Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Insulinoma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a rare form of a neuroendocrine tumor. Most insulinomas are benign in that they grow exclusively at their origin within the pancreas, but a minority metastasize. Insulinomas are one of the functional pancreatic neuroendocrine tumor (PNET) group ("functional" because it increases production of insulin). In the Medical Subject Headings classification, insulinoma is the only subtype of "islet cell adenoma".
Novel peptide, applications and preparation method thereof
InactiveCN102633873AReduce morbidityDelay disease progressionPeptide/protein ingredientsMetabolism disorderDiseaseInsulin secreting adenoma
The invention provides peptide used for preventing and treating diabetes. According to the weak immunogen of antigen polypeptide, a fragment of antigenic epitope (IPALDSLTPANED) derived from HSP60 is inserted into the downstream of a linear B-epitope sequence HGDTTDEYQD in a membrane closing area of insulinoma associated protein 2 to form the peptide. According to the peptide, the generation times of NOD (nonobese diabetic) mice diabetes can be reduced obviously, so that the novel peptide plays the role of preventing and treating I-type diabetes. Meanwhile, the peptide can be used for transgenic animals and recombinant microorganisms, so that the transgenic animals and the recombinant microorganisms can be used for producing the peptide or preparing oral vaccine for preventing and treating diabetes and related diseases of diabetes.
Owner:CHINA PHARM UNIV
New plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
ActiveUS20100322850A1Evaluate effectivenessEarly detectionDisease diagnosisDiagnostic recording/measuringDiseaseDendritic cell
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.
Owner:UNIV LIBRE DE BRUXELIES +2
Novel blood sugar controller and method of screening the same
InactiveUS20050119174A1Impaired glucose tolerancePromote insulin secretionPeptide/protein ingredientsImmunoglobulinsDiseaseScreening method
The present invention provides an impaired glucose tolerance ameliorating drug and a therapeutic drug for lifestyle-related diseases, particular an antidiabetic drug, which contain a CXCR3 agonist as an active ingredient; a hypoglycemia ameliorating drug, a therapeutic drug for insulinoma or an anti-obesity drug containing a CXCR3 antagonist as an active ingredient; a method of screening for a new CXCR3 ligand using CXCR3 and a known CXCR3 ligand; a method of screening a CXCR3 ligand, which uses a co-expression system of CXCR3 and a coupling G protein; and a diagnostic method for type II diabetes, which includes detecting an amount of a CXCR3 ligand expressed in a biological sample.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
B cell epitope for xanthine oxidase and antigen peptide containing epitope and applications thereof
InactiveCN106282136ASingle ingredientSimple structureSenses disorderTumor rejection antigen precursorsWestern blotInsulin secreting adenoma
The invention discloses B cell epitope for xanthine oxidase and an antigen peptide containing the epitope. The antigen peptide is prepared by the following steps: B cell epitope for xanthine oxidase is connected to a linear B cell epitope FEYQD which is at a membrane-proximal region of insulinoma-associated protein-2 by a flexible peptide in a series connection, and a terminal is connected to a N terminal of Th2 auxiliary epitope P2 of P277 by a flexible peptide in a series connection. Serum which is obtained by immunization of mice with the antigen peptide is detected by Western blot, results show that an antibody which is specifically combined with xanthine oxidase is generated, and the antigen peptide is used for detecting xanthine oxidase; serum of the mice which are immunized by the antigen peptide can be used for inhibiting exogenous activity of xanthine oxidase, the difference between the inhibition rate of xanthine oxidase and the inhibition rate of allopurinol is not substantial (P>0.5), and the serum can be used for preparing xanthine oxidase inhibitor; the antigen peptide is used for treating gout, hepatopathy, nephrosis, atherosclerotic, diabetes, senile dementia, eye diseases, cardiovascular diseases, and other diseases due to xanthine oxidase abnormity, uric acid abnormity and oxidative stress disorder with important theoretical values and wide application prospects.
Owner:CHINA PHARM UNIV
Preparation method and purpose of Exendin-4 coupling superparamagnetic iron oxide nano particle
InactiveCN102249345AUniform particle sizeGood dispersionMaterial nanotechnologyFerric oxidesPolyethylene glycolSuperparamagnetic iron oxide
The invention discloses a preparation method of an Exendin-4 coupling superparamagnetism iron oxide nanometer particle. A high temperature hydrolysis of metal alkoxide chelate is employed to prepare an SPIO (superparamagnetic iron oxide) nano particle; an APS ((3-aminopropyl) trimethoxysilane) is employed to carry out silanization modification on the SPIO, and PEG (polyethylene glycol) is employed to carry out a surface coating on an APS-SPIO particle to obtain a PEG-SPIO; an NHS / EDC (N-Hydroxysuccinimide / N-ethyl-N-(3-(dimethylamino)propyl)carbodiimide) method is further employed to couple the Exendin-4 on the PEG-SPIO, so as to obtain a nano-material SPIO-exendin-4 with beta cell targeting. The SPIO-exendin-4 prepared by the method of the invention can be applied to targeting imaging of insulinome and can increase mark efficiency of the SPIO to a beta cell.
Owner:ZHEJIANG UNIV
Use of CBx cannabinoid receptor modulators as potassium channel modulators
InactiveCN101431994AReduce processReduce seizuresNervous disorderMetabolism disorderAppetite regulationEpilepsy
The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and / or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and / or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.
Owner:SOLVAY PHARMA GMBH
Methods of using potassium channel inhibiting compounds
Owner:SOLVAY PHARMA GMBH
A 68ga-labeled exenatide-like compound and its preparation method and application
ActiveCN107325169BHigh tumor imaging sensitivitySmall side effectsRadioactive preparation carriersPeptide preparation methodsChemical compoundInsulin secreting adenoma
The invention discloses <68>Ga marked NOTA-MAL-Cys<39>-exendin-4 compound as well as a preparation method and application thereof. The <68>Ga-NOTA-MAL-Cys<39>-exendin-4 is prepared from <68>Ga marked precursor compound of NOTA-MAL-Cys<39>-exendin-4. Synthesizing time of the <68>Ga-NOTA-MAL-Cys<39>-exendin-4 disclosed by the invention is about 25min, a labeling yield is as high as 80% or more, HPLC determination shows that a product radiochemical purity is larger than 98%, and the marked product of the <68>Ga-NOTA-MAL-Cys<39>-exendin-4 can be specifically combined with glucagon-like peptide-1 receptor (GLP-1R), is a GLP-1 receptor photographic developer having potential and is suitable for being applied to clinical insulinoma diagnosis.
Owner:NANJING FIRST HOSPITAL +1
an exenatide 18 f markers and preparation methods and applications
ActiveCN104109201BImplement anchor tagImprove labeling efficiencyHormone peptidesRadioactive preparation carriersAnserineRadioactive drug
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
InactiveCN101431998ADelay progressReduce seizuresNervous disorderHydroxy compound active ingredientsActive agentAppetite regulation
The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one KATP channel modulator as a first active agent and b) at least one CBx modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and / or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.
Owner:SOLVAY PHARMA GMBH
Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
ActiveUS8425878B2Evaluate effectivenessEarly detectionAnimal cellsIn-vivo radioactive preparationsDiseaseInflammation Process
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.
Owner:UNIV LIBRE DE BRUXELIES +2
Method of Screening Substance Useful in Treating Disease With the Use of GPR40 and Phospholipase
The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
Owner:EISIA R&D MANAGEMENT CO LTD
Application of annexin V
ActiveCN109529017ALower blood sugar levelsImpaired Glucose Tolerance Test (IPGTT)Peptide/protein ingredientsMetabolism disorderCreatinine riseDiabetes model
The invention belongs to the technical field of biology, particularly discloses an application of annexin V to the preparation of a medicine for delaying diabetes progression, and specifically comprises an application of the annexin V to the preparation of a medicine for the in preparing a medicament for improving physiological index and metabolism of diabetes, improving insulin signal pathway ofdiabetic model, improving pathological changes of diabetes liver, pancreas and kidney, improving diabetes serum creatinine and urea nitrogen levels, preventing diabetic renal complications or renal function damage and protecting insulinoma cells from apoptosis caused by diabetes inducer streptozotocin.
Owner:JIANGSU TARGET BIOMEDICINE RES INST +1
Antibodies that recognize iapp
InactiveUS20150110776A1Reduce decreaseReducing IAPP accumulationSugar derivativesBacteriaIGT - Impaired glucose toleranceEpitope
The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Owner:PROTHENA BIOSCI LTD
Antibodies that recognize iapp
InactiveUS20150110777A1Reduce decreaseReducing IAPP accumulationAnimal cellsBacteriaEpitopeIGT - Impaired glucose tolerance
The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Owner:PROTHENA BIOSCI LTD
Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics
InactiveUS20160082137A1Facilitate surgical removalPeptide/protein ingredientsRadioactive preparation carriersChemical compoundPolyethylene glycol
A chemical compound has the general formula: Ex4-linker-Sar(64Cu)-Fl in which Ex4 is an extendin-4 analog; linker is a polyethylene glycol (PEG) chain, for example formed with four ethylene glycol residues; Fl is a photoluminescent moiety, and Sar(64Cu) is an atom of copper-64 chelated in a sarcophagine moiety is useful as a multimodality imaging agent for detection and localization of insulinoma cells and β-cell masses.
Owner:SLOAN KETTERING INST FOR CANCER RES
Exenatide <18>F marker, and preparation method and application thereof
ActiveCN104109201AImplement anchor tagImprove labeling efficiencyHormone peptidesRadioactive preparation carriersRadioactive drugInsulin secreting adenoma
The invention belongs to the field of radioactive drug markers, and concretely relates to a <18>-FBEM-Cys39-Exenatide marker, and a preparation method and an application thereof. The 39th serine (Ser39) at the N-terminal of Exenatide is replaced by cysteine (Cys39) to obtain a novel Exenatide analog, and the specific combination characteristic of the mercapto group of the analog and a marking prosthetic group (<18>-FBEM) is used to realize the positioning marking of Exenatide. Preclinical researches show that the marked product <18>-FBEM-Cys39-Exenatide can be specifically combined with a GLP-1 receptor, is a latent GLP-1 receptor developer, and is suitable for diagnosing insulinoma.
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Antibodies that recognize IAPP
InactiveUS9850302B2Reducing IAPP accumulationReduce accumulationMetabolism disorderAntibody ingredientsIGT - Impaired glucose toleranceEpitope
The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Owner:PROTHENA BIOSCI LTD
Compositions and methods for the treatment of metabolic syndrome
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute hypertension or malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.
Owner:CELLIXBIO PTE LTD
Extracting method and application of plant composition containing radix pseudostellariae
InactiveCN105147842ARich in active ingredientsReduce dosageAntineoplastic agentsPlant ingredientsSchisandra propinquaActive ingredient
The invention provides an extracting method of a plant composition containing radix pseudostellariae. The plant composition is prepared from 100 g of radix pseudostellariae, 80 g of humulus lupulus, 50 g of ctenium aromaticum and 170 g of schisandra propinqua and is prepared through the microwave extraction method. In this way, the content is greatly increased, and the usage amount is reduced. The invention further provides an application of the plant composition containing radix pseudostellariae in preparation of medicine for restraining brown rat insulinoma epithelium RIN-m proliferation.
Owner:南京多宝生物科技有限公司
Application of insulinoma-related protein 1 as marker for diagnosing or prognostically evaluating prostate neuroendocrine small cell carcinoma
PendingCN112213486AHigh sensitivityImprove featuresMaterial analysisSmall-cell carcinomaAdenocarcinoma
The invention belongs to the field of biomedicine, and provides application of insulinoma related protein 1 in preparation of a marker for diagnosis or prognosis evaluation of prostate neuroendocrinesmall cell carcinoma. The invention also provides a kit which comprises a reagent for detecting the insulinoma related protein 1. The marker INSM1 can be used for effectively distinguishing an adenocarcinoma accompanied by neuroendocrine differentiation subject from an adenocarcinoma accompanied by penem cell-like neuroendocrine differentiation subject so that accurate pathological detection of prostate cancer is realized; meanwhile, the marker has a good indication effect in the aspect of adenocarcinoma accompanied by neuroendocrine differentiation diagnosis, and has higher sensitivity and specificity compared with a clinically common diagnosis marker so that the occurrence of clinical misdiagnosis and missed diagnosis is reduced. In addition, the marker also has a good prediction effecton prognosis of prostate cancer, and is beneficial to recurrence monitoring and clinical early intervention of a subject.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Compositions and methods for the treatment of metabolic syndrome
The invention relates to compounds of Formula I:and its pharmaceutical acceptable salts, solvates, enantiomers, stereoisomers and hydrates thereof. Compounds of Formula I and and compositions comprising Formula I are used to treat patients with metabolic syndrome and may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral administration, as a syrup, or for injection. More specifically, compounds and compositions of Formula I may be used to treatment of acute hypertension or-malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.
Owner:CELLIXBIO PTE LTD
Peptide, applications and preparation method thereof
InactiveCN102633873BPrevent diabetesPlay a supporting rolePeptide/protein ingredientsMetabolism disorderDiseaseInsulin secreting adenoma
Owner:CHINA PHARM UNIV
Method for judging tumor-susceptible mouse model
InactiveCN107550932AEvaluate growthShort cycleMammal material medical ingredientsIn-vivo testing preparationsDynamic monitoringTumor microenvironment
The invention belongs to the field of tumor research and treatment and particularly relates to a method for judging a tumor-susceptible mouse model. The proliferation situation of insulinoma cell canbe directly reacted through dynamic monitoring of blood glucose in a mouse; when the insulin in the mouse reaches a certain limit, the mouse can die of severe hypoglycemia caused by excessive insulinsecretion, and the reason is caused by the proliferation of the MIN6 cells; as a tumor microenvironment existing in a mouse body promotes the proliferation, mice living under the same conditions are proved to be prone to tumors, which is the tumor-susceptible mouse model.
Owner:中国医科大学
Method of screening substance useful in treating disease with the use of GPR40 and phospholipase
The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
Owner:EISIA R&D MANAGEMENT CO LTD
Application of D1 receptor-based targeting molecular probe in pancreatic beta cell imaging
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Antibodies that recognize IAPP
InactiveUS9951131B2Reducing IAPP accumulationReduce accumulationMetabolism disorderAntibody ingredientsEpitopeIGT - Impaired glucose tolerance
The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Owner:PROTHENA BIOSCI LTD
Recombinant G-17 protein, gene for encoding recombinant protein and application of gene for encoding recombinant protein
PendingCN111116730ARealize specific detection and identificationHigh detection sensitivityBacteriaMicroorganism based processesAntigen epitopeAntigen
The invention provides recombinant G-17 protein, a gene for encoding the recombinant protein and application of the gene for encoding the recombinant protein. An amino acid sequence of the recombinantG-17 protein is shown in SEQ ID NO: 1 as shown in the description, and a base sequence of the gene for encoding the recombinant G-17 protein is shown in SEQ ID NO: 2 as shown in the description. According to the recombinant G-17 protein, the gene for encoding the recombinant protein and application of the gene for encoding the recombinant protein, after a G-17 antigen epitope sequence is connected with a sequence of a B cell epitope of insulinoma-related protein IA-2 and a Th2 cell epitope of a C terminal of P277 through flexible fragments, the amino acid sequence of the recombinant G-17 protein is formed; and mice are immunized against the recombinant G-17 protein, and an ELISA detection antibody titer value reaches 1:106, so that specific detection and recognition of G-17 are achieved,not only is the detection sensitivity enhanced, but also distortion of a detection result is avoided, the probability of subsequent screening of a high-specificity antibody is improved, and the time and the economic cost are saved.
Owner:南京拂晓生物科技有限公司
Application of beta-catenin and gene
InactiveCN103060463ARapid diagnosisAccurate diagnosisMicrobiological testing/measurementBiological testingBeta-cateninIslet cell tumors
The invention belongs to the field of biological medicine, and in particular relates to an application of beta-catenin and gene in a reagent for detecting insulinoma and an application of the beta-catenin and gene in drug screening of insulinoma drugs. Through the experiments of dissecting the remain of a transgenic mice, detecting the blood sugar and fasting insulin level, the influence relation of the beta-catenin to the generation of the insulinoma is researched. The experiment result shows that the beta-catenin and the insulinoma are in positive relation, once the lack of beta-catenin, the occurrence rate of the islet cell tumor is obviously reduced. The application provided by the invention has the beneficial effects that the mice with insulinoma can be fast and accurately diagnosed through the detection of beta-catenin, and the experimental data and theoretical basis are provided for the application of beta-catenin in the reagent for detecting the insulinoma and in the drug screening of the insulinoma drug in the clinical diagnosis.
Owner:SHANGHAI INST FOR ENDOCRINE & METABOLIC DISEASES
Treating Insulin Secreting Cells
InactiveUS20110257250A1Polypeptide with localisation/targeting motifGenetic material ingredientsAdenocarcinomaInsulin Secreting Cell
This invention relates to a recombinant nucleic acid for an RIP-tk (rat insulin promoter-thymidine kinase) construct that selectively targets insulin secreting cells, such as β-cells, PDX-1 positive human pancreatic ductal carcinomas, and other cells containing certain transcription factors. The present invention is useful in the treatment of pancreatic cancers, such as β-cell insulinomas and can also be used to target pancreatic tumors that do not express insulin, such as pancreatic adenocarcinoma.
Owner:BRUNICARDI F CHARLES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com